Fresh off a vitriolic activist battle that spurred the ouster of three board members, Exelixis plans to hydrate its pipeline with artificial intelligence. The company, known for solid tumor med ...

An Insilico Medicine drug candidate spawned by the company’s artificial intelligence technology now has clinical data showing breathing improvement in patients who have a debilitating lung disorder.

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...

Exelixis Inc. EXEL is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insilico Medicine’s generative artificial intelligence ...

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple ...

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine’s artificial intelligence (AI) platform, with potent activity in BRCA-mutated ...

Cambridge, MA, June 16 — Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing ...

Massachusetts-based Insilico's proprietary generative AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific research and generative chemistry for drug discovery. The company says ...

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 million to carry forward its artificial intelligence-powered drug design ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...